Island Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	2018 - 2020
Operating Revenue	0.11	1.25	-	-	-	Upgrade
Other Revenue	0.01	0.01	-	-	-	Upgrade
Revenue	0.12	1.26	-	-	-	Upgrade
Revenue Growth (YoY)	-90.57%	-	-	-	-	Upgrade
Cost of Revenue	1.4	2.27	1.14	-	-	Upgrade
Gross Profit	-1.29	-1.01	-1.14	-	-	Upgrade
Selling, General & Admin	2.33	1.85	1.77	1.78	2.14	Upgrade
Research & Development	-	-	-	1.03	0	Upgrade
Operating Expenses	2.67	1.85	1.77	2.81	2.14	Upgrade
Operating Income	-3.96	-2.86	-2.91	-2.81	-2.14	Upgrade
Interest Expense	-0.03	-0.05	-0.01	-	-	Upgrade
Interest & Investment Income	0.06	0	0.01	-	-	Upgrade
Currency Exchange Gain (Loss)	0	0.04	0.08	0.2	0.01	Upgrade
Pretax Income	-3.92	-2.86	-2.83	-2.61	-2.13	Upgrade
Net Income	-3.92	-2.86	-2.83	-2.61	-2.13	Upgrade
Net Income to Common	-3.92	-2.86	-2.83	-2.61	-2.13	Upgrade
Shares Outstanding (Basic)	173	90	81	81	19	Upgrade
Shares Outstanding (Diluted)	173	90	81	81	19	Upgrade
Shares Change (YoY)	91.98%	11.11%	0.42%	334.32%	-	Upgrade
EPS (Basic)	-0.02	-0.03	-0.03	-0.03	-0.11	Upgrade
EPS (Diluted)	-0.02	-0.03	-0.03	-0.03	-0.11	Upgrade
Gross Margin	-	-80.14%	-	-	-	Upgrade
Operating Margin	-3326.06%	-227.00%	-	-	-	Upgrade
Profit Margin	-3296.73%	-227.04%	-	-	-	Upgrade
EBIT	-3.96	-2.86	-2.91	-2.81	-2.14	Upgrade
EBIT Margin	-	-227.00%	-	-	-	Upgrade
Revenue as Reported	0.18	1.27	0.01	-	-	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.